HBeAg-positive CHRONIC HEPATITIS B
Peginterferon alfa-2a vs lamivudine. George Lau and associates conducted a partially double-blind study in which 814 patients with HBeAg-positive chronic hepatitis B were randomized to receive 48 weeks of (1) peginterferon alfa-2a 180 µg once weekly subcutaneously plus oral placebo, (2) peginterferon alfa-2a plus oral lamivudine 100 mg/day, or (3) lamivudine alone. At week 72, more patients who received peginterferon-containing therapy than patients who received lamivudine monotherapy achieved HBeAg seroconversion (P <0.001), hepatitis B surface antigen (HBsAg) seroconversion (P = 0.001), or serum HBV DNA levels <100,000 copies/mL (P = 0.01). No differences in efficacy were observed between the 2 peginterferon-containing groups. Serious adverse events occurred in 4%, 6%, and 2% of patients in the peginterferon alfa-2a plus placebo, combination therapy, and lamivudine monotherapy treatment groups, respectively. This study showed that peginterferon treatment of patients with HBeAg-positive chronic hepatitis B results in superior outcomes compared with lamivudine monotherapy and that the addition of lamivudine to peginterferon does not increase the rate of off-treatment response. (Lau GKK, et al. N Engl J Med. 2005;352:2682–2695) | 
发表于 2005-9-8 03:12
